Literature DB >> 24850663

Immunohistological insight into the correlation between neuropilin-1 and epithelial-mesenchymal transition markers in epithelial ovarian cancer.

Sirin A I Adham1, Ibtisam Al Harrasi2, Ibrahim Al Haddabi2, Afrah Al Rashdi2, Shadia Al Sinawi2, Abdullah Al Maniri2, Taher Ba-Omar2, Brenda L Coomber2.   

Abstract

The mechanism by which neuropilin-1 (NRP-1) induces malignancy in Epithelial Ovarian Cancer (EOC) is still unknown. This study is the first to demonstrate the relationship between NRP-1 expression and EMT markers vimentin, N-cadherin, E-cadherin and Slug. We used tissue microarrays containing the three main subtypes of EOC tumors: serous, mucinous cystadenocarcinoma and endometrioid adenocarcinoma and representative cases retrieved from our pathology archives. Immunohistochemistry was performed to detect the expression levels and location of NRP-1 and the aforementioned EMT proteins. NRP-1 was mainly expressed on cancer cells but not in normal ovarian surface epithelium (OSE). The Immunoreactive Scoring (IRS) values revealed that the expression of NRP-1, Slug and E-cadherin in the malignant subtypes of ovarian tissues was significantly higher (5.18 ± 0.64, 4.84 ± 0.7, 4.98 ± 0.68, respectively) than their expression in the normal and benign tissues (1.04 ± 0.29, 0.84 ± 0.68, 1.71 ± 0.66, respectively), with no significant differences among the studied subtypes. Vimentin was expressed in the cancer cell component of 43% of tumors and it was exclusively localized in the stroma of all mucinous tumors. The Spearman's rho value indicated that NRP-1 is positively related to the EMT markers E-cadherin and Slug. This notion might indicate that NRP-1 is a partner in the EMT process in EOC tumors.
© The Author(s) 2014.

Entities:  

Keywords:  E-cadherin; EMT; OSE; biomarker; neuropilin-1; slug; vimentin

Mesh:

Substances:

Year:  2014        PMID: 24850663     DOI: 10.1369/0022155414538821

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  15 in total

1.  Downregulation of MLL3 in esophageal squamous cell carcinoma is required for the growth and metastasis of cancer cells.

Authors:  Manhui Xia; Lifang Xu; Yunhua Leng; Feng Gao; Hong Xia; Diandian Zhang; Xuewu Ding
Journal:  Tumour Biol       Date:  2014-10-02

2.  Relationship between neuropilin-1 expression and prognosis, according to gastric cancer histology.

Authors:  Ho Seok Seo; Jiyeon Hyeon; In Hye Song; Han Hong Lee
Journal:  J Mol Histol       Date:  2020-04-02       Impact factor: 2.611

3.  Modeling Neoadjuvant chemotherapy resistance in vitro increased NRP-1 and HER2 expression and converted MCF7 breast cancer subtype.

Authors:  Noura Al-Zeheimi; Sirin A Adham
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 8.739

4.  Circulating soluble neuropilin-1 in patients with early cervical cancer and cervical intraepithelial neoplasia can be used as a valuable diagnostic biomarker.

Authors:  Shouhua Yang; Henghui Cheng; Zaiju Huang; Xiaoling Wang; Yinglu Wan; Jing Cai; Zehua Wang
Journal:  Dis Markers       Date:  2015-03-19       Impact factor: 3.434

Review 5.  Neuropilin-1 as Therapeutic Target for Malignant Melanoma.

Authors:  Grazia Graziani; Pedro M Lacal
Journal:  Front Oncol       Date:  2015-06-03       Impact factor: 6.244

6.  Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.

Authors:  Adviti Naik; Noura Al-Zeheimi; Charles Saki Bakheit; Marwa Al Riyami; Adil Al Jarrah; Mansour S Al Moundhri; Zamzam Al Habsi; Maysoon Basheer; Sirin A Adham
Journal:  Sci Rep       Date:  2017-06-12       Impact factor: 4.379

7.  A novel association of neuropilin-1 and MUC1 in pancreatic ductal adenocarcinoma: role in induction of VEGF signaling and angiogenesis.

Authors:  R Zhou; J M Curry; L D Roy; P Grover; J Haider; L J Moore; S-T Wu; A Kamesh; M Yazdanifar; W A Ahrens; T Leung; P Mukherjee
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

8.  Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma.

Authors:  Pratiek N Matkar; Krishna Kumar Singh; Dmitriy Rudenko; Yu Jin Kim; Michael A Kuliszewski; Gerald J Prud'homme; David W Hedley; Howard Leong-Poi
Journal:  Oncotarget       Date:  2016-10-25

9.  Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells.

Authors:  Adviti Naik; Aida Al-Yahyaee; Nada Abdullah; Juda-El Sam; Noura Al-Zeheimi; Mahmoud W Yaish; Sirin A Adham
Journal:  BMC Cancer       Date:  2018-05-05       Impact factor: 4.430

10.  A formulation of pancreatic pro-enzymes provides potent anti-tumour efficacy: a pilot study focused on pancreatic and ovarian cancer.

Authors:  Macarena Perán; Elena López-Ruiz; María Ángel García; Shorena Nadaraia-Hoke; Ralf Brandt; Juan A Marchal; Julian Kenyon
Journal:  Sci Rep       Date:  2017-10-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.